Biomedical Engineering Reference
In-Depth Information
58. Ton NC, Parker GJ, Jackson A, Mullamitha S, Buonaccorsi GA, Roberts C, Watson Y, Davies
K, Cheung S, Hope L, Power F, Lawrance J, Valle J, Saunders M, Felix R, Soranson JA, Rolfe
L, Zinkewich-Peotti K, Jayson GC (2007) Phase I evaluation of CDP791, a PEGylated di-Fab'
conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res
13:7113-7118
59. Davidson BL, McCray PB Jr (2011) Current prospects for RNA interference-based therapies.
Nat Rev Genet 12:329-340
60. Lares MR, Rossi JJ, Ouellet DL (2010) RNAi and small interfering RNAs in human disease
therapeutic applications. Trends Biotechnol 28:570-579
61. Joralemon MJ, McRae S, Emrick T (2010) PEGylated polymers for medicine: from conjuga-
tion to self-assembled systems. Chem Commun (Camb) 46:1377-1393
62. Tamura M, Ichinohe S, Tamura A, Ikeda Y, Nagasaki Y (2011) In vivo and in vitro
characteristics of core-shell-type nanogel particles: optimization of core cross-linking density
and surface PEG density in PEGylated nanogels. Acta Biomaterialia. doi:10.1016/j.
actbio.2011.05.027
63. Oishi M, Nagasaki Y (2010) Stimuli-responsive smart nanogels for cancer diagnostics and
therapy. Nanomedicine (Lond) 5:451-468
64. Elbayoumi TA, Torchilin VP (2008) Liposomes for targeted delivery of antithrombotic drugs.
Expert Opin Drug Deliv 5:1185-1198
65. Jiang W, Lionberger R, Yu LX (2011) In vitro and in vivo characterizations of PEGylated
liposomal doxorubicin. Bioanalysis 3:333-344
66. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev
Drug Discov 4:145-160
67. Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols
effectively prolong the circulation time of liposomes. FEBS Lett 268:235-237
68. Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K (1991) Toxicity and
antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its
extremely long circulation in blood. Cancer Res 51:3229-3236
69. Alakhov V, Klinski E, Lemieux P, Pietrzynski G, Kabanov A (2001) Block copolymeric
biotransport carriers as versatile vehicles for drug delivery. Expert Opin Biol Ther 1:583-602
70. Matsumura Y, Kataoka K (2009) Preclinical and clinical studies of anticancer agent-
incorporating polymer micelles. Cancer Sci 100:572-579
71. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K,
Matsumura Y, Kataoka K (2003) Novel cisplatin-incorporated polymeric micelles can eradi-
cate solid tumors in mice. Cancer Res 63:8977-8983
72. Bae Y, Kataoka K (2009) Intelligent polymeric micelles from functional poly(ethylene
glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev 61:768-784
73. Karakoti AS, Das S, Thevuthasan S, Seal S (2011) PEGylated inorganic nanoparticles. Angew
Chem Int Ed Engl 50:1980-1994
74. Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA,
Graham D, Wheate NJ (2010) Gold nanoparticles for the improved anticancer drug delivery of
the active component of oxaliplatin. J Am Chem Soc 132:4678-4684
75. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA (2006) Oligonu-
cleotide-modified gold nanoparticles for intracellular gene regulation. Science 312:1027-1030
76. Visaria RK, Griffin RJ, Williams BW, Ebbini ES, Paciotti GF, Song CW, Bischof JC (2006)
Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-
alpha delivery. Mol Cancer Ther 5:1014-1020
77. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr, Gannon WE, Walker M, Seidel GD,
Yuldasheva N, Tamarkin L (2010) Phase I and pharmacokinetic studies of CYT-6091, a novel
PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16:6139-149
78. Ishii T, Otsuka H, Kataoka K, Nagasaki Y (2004) Preparation of functionally Pegylated
gold nanoparticles with narrow distribution through autoreduction of auric cation by alpha-
biotinyl-PEG-block-[poly (2-(N, N-dimethylamino) ethyl methacrylate)]. Langmuir 20:561-564
